Monday, 23 April 2012

European Medicines Agency report on fingolimod safety review

Source MS Trust:
The European Medicines Agency has issued advice on the management of fingolimod (Gilenya) treatment to help reduce the risk of heart problems after the first dose
The European Medicines Agency (EMA) started a review of fingolimod after there were reports of people experiencing heart problems, cases of sudden or unexplained deaths, and the death of a person in the US within 24 hours of receiving their first dose.